Compare ClearPoint Neuro Inc (CLPT) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Oklo Inc — how do they compare? ClearPoint Neuro Inc trades at $15.3 (market cap $454.21M), while Oklo Inc trades at $45.51 (market cap $8.74B). The key difference: Oklo Inc is far larger — about 19.2× ClearPoint Neuro Inc's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | OKLO | |
|---|---|---|
Market Cap | $454.21M | $8.74B |
Sector | Health | Technology |
52-Week High | $29.60 | $174.14 |
52-Week Low | $8.66 | $36.84 |
Enterprise Value | $488.79M | $6.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
OKLO trades at $45.13, up 1.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $77.07. The company reported its first revenue of $1.2 million in Q2 2026 but posted a wider net loss of $0.28 per share, missing estimates. Key milestones include the Groves reactor achieving criticality, though cash burn remains high with operating cash flow negative $117 million in 2026.
The outlook balances significant growth potential in nuclear energy against substantial execution risks. Analyst sentiment is strongly bullish (77% buy ratings), but investors face risks from persistent losses, high spending, and project delays. The stock's trajectory hinges on successful commercialization of its Aurora reactors by the targeted 2028 startup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
